Modality
mRNA
MOA
CAR-T BCMA
Target
PSMA
Pathway
PI3K/AKT
IgAN
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
~Aug 2022
→ ~Nov 2023
Phase 2
Feb 2024
→ Nov 2027
Phase 2Current
NCT07634168
450 pts·IgAN
2024-02→2027-11·Not yet recruiting
450 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-016mo agoPh1 Dose Esc· IgAN
2027-11-171.6y awayPh3 Readout· IgAN
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Not yet…
Catalysts
Ph1 Dose Esc
2025-10-01 · 6mo ago
IgAN
Ph3 Readout
2027-11-17 · 1.6y away
IgAN
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07634168 | Phase 2/3 | IgAN | Not yet recr... | 450 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| BGN-3859 | BeiGene | Approved | PSMA |